Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ArQule -- Ignore unavailable to you. Want to Upgrade?

To: John Dwyer who wrote (165)	2/4/1998 12:44:00 PM
From: ahhaha	Read Replies (1) \| Respond to of 399

Uncle! I misspoke. The science is "fair", not "poor". My problem is earnings visibility, not potential to help mankind. God hears all prayers. Molecular manipulation is fine as long as what comes out is recognized as another chemical. We have a chemical design process. To extrapolate that into drug design process exceeds the leap of faith. But if they are only chemical recombinatorants, we don't have the added value of finding something that can be sold at high prices, because the recombination with null twist is cheaply reproducible, thus imitatable. Patents won't protect against a competitor introducing another variant with the equivalent functionality. It's findable because it's combinatoric and findable using the ARQL Wheel! You don't have the horrible and proprietary discovery process that is genius. Anyone can spin a Prayer Wheel. ps. It's nice to hear from someone with a balanced view on this thread.